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ABSTRACT: Total syntheses of HMP-Y1, atrop-HMP-Y1, hibarimicinone, atrop-hibarimicinone, and HMP-P1 are described using a two-
directional synthesis strategy. A novel benzyl fluoride Michael–Claisen reaction sequence was developed to construct the complete carbon 
skeleton of HMP-Y1 and atrop-HMP-Y1 via a symmetrical, two-directional, double annulation. Through efforts to convert HMP-Y1 deriva-
tives to hibarimicinone and HMP-P1, a biomimetic mono-oxidation to desymmetrize protected HMP-Y1 was realized. A two-directional 
unsymmetrical double annulation and biomimetic etherification were developed to construct the polycyclic and highly-oxidized skeleton of 
hibarimicinone, atrop-hibarimicinone, and HMP-P1. The use of a racemic biaryl precursor allowed for the synthesis of both hibarimicinone 
atropisomers and provides the first confirmation of the structure of atrop-hibarimicinone. Additionally, this work documents the first report-
ed full characterization of atrop-hibarimicinone, HMP-Y1, atrop-HMP-Y1, and HMP-P1. Lastly, a pH-dependent rotational barrier about the 
C2–C2' bond of hibarimicinone was discovered, which provides valuable information necessary to achieve syntheses of the glycosylated con-
geners of hibarimicinone. 
INTRODUCTION 
Background.  Hibarimicins  A–G  are  complex  pseudo-dimeric 
type-II polyketides isolated from the culture broth of the rare acti-
nomycete  Microbispora  rosea  subsp.  hibaria  TP-A0121.
1  These 
metabolites inhibit proliferation and induce differentiation of nu-
merous human cancer cell lines. In particular, hibarimicin B (1, 
Figure 1), which is identical to angelmicin B,
1b,c has the most potent 
anti-proliferative  activity  in  HL-60  cells  (IC50  =  58  nM).
1h  The 
cellular target and biological mechanism of action of 1 remain 
Figure 1. Structure of hibarimicin B (1). 
undetermined.  The  hibarimicins  are  amongst  the  most  complex 
and largest type-II polyketides known. Hibarimicins A–G share an 
unprecedented  highly-oxidized  aglycon,  hibarimicinone  (2a, 
Scheme 1). The C2-symmetry of 2a is broken by oxidation of the B-
, C-, and D-rings relative to the G-, F-, and E-rings, respectively. 
More specifically, the B-ring contains a cyclic ether bridging C8' 
and C13', the C-ring contains a hydroxyl group at C6', and the D-
ring is a quinone. Furthermore, 2a exhibits axial chirality about its 
highly congested C2–C2' bond and is isolated as a single atropiso-
mer.
1i,2 Altogether, the hibarimicins and hibarimicinone (2a) are 
challenging targets that have resisted total synthesis
3 until earlier 
this year when Tatsuta et al. reported the first total synthesis of 2a.
4 
Herein, we report enantioselective total syntheses of hibarimici-
none (2a) and atrop-hibarimicinone (2b), and the first total syn-
theses  of  the  biosynthetically  related  natural  product  aglycons 
HMP-Y1 (3a), atrop-HMP-Y1 (3b) and HMP-P1 (6) (Scheme 1). 
Scheme 1. Proposed Biosynthetic Conversion of HMP-Y1 (3a) 
to Hibarimicinone (2a) and HMP-P1 (6) 
 
Biosynthesis  Hypothesis.  Mutagenesis  of  Microbispora  rosea 
subsp. hibaria TP-A0121 led to the identification of novel metabo-
lites, including HMP-Y1 (3a), HMP-P1 (6), and their glycosylated 
derivatives (Scheme 1).
1f Through 
13C-acetate labeling studies, it 
was discovered that C2-symmetric 3a is a precursor to 2a, which is 
subsequently glycosylated to yield hibarimicins A–G. Ostensibly, 
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this conversion (3a → 2a) proceeds by breaking the C2-symmetry 
of 3a via oxidation of the B-, C-, and D-rings and demethylation of 
the C4'–OMe methyl group. We postulated that a single desymme-
trizing  oxidation  of  the  C-ring  of  3a  to  hypothetical  quinone  4 
would be sufficient to relay oxidation to the B- and D-rings. This 
could be achieved via (1) tautomerization of quinone 4 to C8'-
ortho-quinone methide 5 with subsequent oxy-Michael addition of 
the C13'–OH to install the B-ring cyclic ether, (2) re-oxidation of 
the C-ring, and (3) transposition of the C-ring quinone to the D-
ring  with  concomitant  demethylation  to  give  2a.  HMP-P1  (6) 
arises from 2a via cyclization of C1–OH onto C3' of the D-ring 
quinone and subsequent expulsion of methanol.
1f 
Results and Discussion 
Scheme  2.  Biosynthesis-Inspired  Retrosynthesis  Analysis  of 
HMP-Y1 (3a), Hibarimicinone (2a), and HMP-P1 (6) 
 
Synthesis Plan. Inspired by our proposed biosynthetic relay ox-
idation scheme, we envisioned that a similar set of biomimetic ret-
rosynthetic disconnections could simplify 2a to two plausible pre-
cursors, C2-symmetric octacycle 7 and pseudo-C2-symmetric octa-
cycle 8 (Scheme 2). Targeting 7 was attractive for two reasons: (1) 
global deprotection would yield HMP-Y1 (3a) and (2) it would 
allow direct assessment of the feasibility of a biomimetic mono-
oxidation to access a quinone analogous to 4. In contrast to 7, the 
C2-symmetry of 8 is perturbed by the presence of a benzyl group
5 
and  the  C6'–OH  (both  highlighted  in  red),  the  latter  of  which 
would facilitate chemoselective C-ring oxidation to a quinone. The 
most noteworthy feature shared by both 7 and 8 is the degeneracy 
of the AB- and HG-ring systems that result from the retrosynthetic 
excision of the B-ring cyclic ether bond. Next, it was envisioned that 
both octacyclic systems could be constructed in a single operation 
via a two-directional double annulation,
6 where the dianion of biar-
yl 10 would react with two equivalents of the AB-/HG-enone (+)-
9. The use of a symmetric biaryl annulation donor would lead to 7 
whereas the employment of an unsymmetrical variant, with addi-
tional oxidation at C6', would result in 8. Both of these strategies 
are convergent and circumvent the need to construct the hindered 
C2–C2' bond at a late stage. Efforts by the Roush group to form the 
C2–C2' bond in simple model systems via cross-coupling were met 
with difficulty.
3d At the outset of our study, the configuration of the 
stereochemical axis about the C2–C2' bond of hibarimicinone (2a) 
was ambiguous.
1i Consequently, we elected to proceed with race-
mic biaryl annulation donor 10 to prepare and characterize both 
atropisomers of HMP-Y1 (3a) and hibarimicinone (2a). 
Synthesis of the AB-/HG-Enone (+)-9. We previously reported a 
gram-scale  enantiospecific  synthesis  of  the  AB-/HG-ring  system 
corresponding to the unnatural enantiomer of 2a.
3i The AB-/HG-
enone (+)-16 (Scheme 3), with stereochemistry corresponding to 
the natural enantiomer of 2a, was prepared from key intermediate 
cyclohexenone (+)-15 following an analogous series of diastereose-
lective transformations. Notably, both enantiomers of (+)-15 were 
accessed from α-D-methyl-glucopyranoside by taking advantage of 
its latent C2-symmetry. The AB-/HG-enone synthesis commenced 
with AcOH-mediated deprotection of benzylidene acetal 11 fol-
lowed by selective Wittig iodination of the resultant primary hy-
droxyl group to provide diol (+)-12. Next, chemoselective monosi-
lylation of (+)-12 with TBSCl was accomplished by exploiting a 
subtle steric difference between its two secondary hydroxyl groups. 
The remaining secondary hydroxyl group was then pivoylated un-
der forcing conditions to furnish differentially protected pyranose 
(+)-13. Exposure of (+)-13 to DBU promoted elimination of the 
primary iodide to generate exocyclic enol ether (+)-14, which un-
derwent type-II Ferrier rearrangement upon treatment with catalyt-
ic  Hg(OCOCF3)2.
7  The  resultant  β-hydroxy-cyclohexanone  was 
dehydrated  to  provide  (+)-15.  Following  our  previous  proce-
dures,
3i (+)-15 was converted to (+)-16
8 and the tertiary C14–OH 
was ultimately TMS-protected to give annulation acceptor (+)-9. 
Scheme 3. Synthesis of the AB-/HG-enone (+)-8 
 
aConditions:  (a)  AcOH/H2O,  80  °C;  (b)  PPh3,  I2,  imidazole, 
PhMe/CH2Cl2, RT → 45 °C, 76% (two steps); (c) TBSCl, imidazole, 
CH2Cl2, 0 °C → RT, 99%; (d) PivCl, 4-DMAP, ClCH2CH2Cl, 50 °C, 
94%;  (e)  DBU,  MeCN,  80  °C,  75%;  (f)  30  mol%  Hg(OCOCF3)2, 
Me2CO/H2O; (g) MsCl, Et3N, CH2Cl2, 0 °C → RT, 74% (two steps); 
(d) LiHMDS, THF, 0 °C; then TMSOTf, 0 °C → RT, 99%. 
Demonstration of a Biomimetic Etherification on a Model 
ABCD-Ring System. A key transformation in our synthesis plan is 
a late-stage biomimetic etherification that retrosynthetically sym-
metrizes hibarimicinone (2a) and HMP-P1 (6). Consequently, a 
model ABCD-ring system was first investigated to test the viability 
of this proposed reaction. Kraus annulation
9 of cyanophthalide 17
10 
with ent-AB-/HG-enone ent-9
8 under rigorously oxygen-free condi-
tions  gave  ABCD-tetracycle  (–)-18  (Scheme  4).  Deoxygenation 
was critical for the success of the annulation, as adventitious oxygen 
caused decomposition. (–)-18 was then oxidized with DDQ to the 
corresponding C-ring quinone, which upon exposure to anhydrous 
HCl led to clean formation of pentacyclic ether (+)-20. This trans-
formation presumably occurs through the intermediacy of ortho-
quinone methide 19,
11 which is trapped by the proximal acetonide  
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Scheme 5. Synthesis of HMP-Y1 (3a) and atrop-HMP-Y1 (3b) via a Benzyl Fluoride Michael–Claisen Reaction Sequence 
 
aConditions: (a) Me2SO4, K2CO3, Me2CO, 98%; (b) mCPBA, NaHCO3, CH2Cl2; then Na2CO3, MeOH; (c) NaH, MOMCl, DMF, 0 °C → RT, 91% 
(two steps); (d) nBuLi, TMEDA, THF, –78 → 0 °C; then FeCl3, 0 °C → RT, 76%; (e) Br2, Py, CH2Cl2, 0 °C, 91%; (f) nBuLi, THF, –78 °C; then 
ClC(O)OMe, –78 °C → RT, 89%; (g) LiTMP, THF, –78 °C; then (BrCF2)2, –78 °C, 62%; (h) TBAT, MeCN, 82 °C, 75%; (i) (+)-9, LiTMP, THF, 
–78 °C; then HMDS, –78 → –35 °C; then MgBr2•OEt2, –35 → 0 °C; (j) CF3CH2OH/H2O, NaHCO3, 80 °C, 55% (two steps); (k) aq. HF, 
MeCN/THF, 50 °C; (l) H2, Pd(OH)2/C, THF; for 3a, 59% (two steps); for 3b, 62% (two steps). 
Scheme 4. Synthesis of an ABCD-Pentacyclic Model System 
 
aConditions:  (a)  LiHMDS,  THF,  –78  →  0  °C,  94%;  (b)  DDQ, 
CH2Cl2, –20 °C; (c) HCl, CH2Cl2, 0 °C, 69% (two steps). 
oxygen with concomitant acetonide cleavage. Notably, this acid-
mediated  etherification  required  high  dilution  in  order  to  avoid 
formation of (–)-18 and decomposition products, potentially via 
intermolecular processes.
11c We propose that acetonide cleavage is 
triggered by its proximity to the reactive ortho-quinone methide 
intermediate due to the failure to isolate any acetonide cleavage 
products that lack the cyclic ether bond. This concept is further 
justified by later observations on the dimeric system, where only 
the acetonide of A-ring is cleaved whereas the G-ring acetonide 
remains  intact  (vide  infra).  Overall,  the  model  oxidation-
etherification sequence afforded excellent precedence for our sub-
sequent studies. 
Development of a Benzyl Fluoride Michael–Claisen Reac-
tion Sequence to Achieve the First Total Synthesis of HMP-Y1 
(3a) and atrop-HMP-Y1 (3b). Our synthesis plan for HMP-Y1 
(3a) involved a symmetric two-directional double annulation to 
generate  C2-symmetric  octacycle  7,  which  could  potentially  be 
desymmetrized  through  a  biomimetic  mono-oxidation  to  access 
hibarimicinone (2a) and HMP-P1 (6). Such an ambitious double 
annulation strategy required a flexible synthesis of symmetric biaryl 
annulation donors in which different substituents at C6/C6' could 
be introduced, due to the lack of robust annulation sequences to 
generate  naphthols  (1-hydroxynaphthalenes  rather  than  1,4-
dihydroxynaphthalenes, i.e., hydroquinones).
12 Our biaryl synthesis 
began with 5-methylvanillin 21
13 (Scheme 5), which was converted 
to trialkoxytoluene 22  in a three step process involving: (1) O-
methylation, (2) Dakin oxidation followed by in situ formate meth-
anolysis, and (3) MOM protection of the resultant phenol. Next, 
regioselective  ortho-lithiation  of  22  at  C2'  and  FeCl3-mediated 
oxidative dimerization of the resultant aryllithium species delivered 
biaryl (±)-23. Carbomethoxy groups were then installed in a two-
step  sequence  involving  bromination  and  lithium–halogen  ex-
change followed by acylation to afford bis-ortho-toluate (±)-24. 
The reaction kinetics and ultimate success of Michael–Claisen 
reaction sequences
14 hinges on numerous factors. These include, 
but are not limited to: (1) the stability and nucleophilicity of the 
reacting carbanion,
15 (2) the stability of the electrophilic acceptor 
to the base required to deprotonote the donor,
16 and (3) the steric 
bulk of the donor (substituents at C6/C6' and the ester side chain) 
and of the acceptor. Furthermore, the slow step of the tandem reac-
tion sequence will change based on the particular donor and accep-
tor used. We found that (±)-24 could be deprotonated twice by 
LiTMP  and  that  the  corresponding  dianion  underwent  two-
directional bis-Michael–Claisen reaction sequence with various 2-
cyclohexenones, including the AB-/HG-enone ent-9. However, the 
slow rate of both the Michael and Claisen reactions
17 of the se-
quence  with  sterically  encumbered  ent-9  versus  simpler  2-
cyclohexenones coupled with the finite lifetime of the dianion of 
(±)-24 led to very low yields (<10%) of the desired octacyclic di-
hydronaphthalene products. Attempts to facilitate the Claisen step 
22
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of the reaction sequence by utilizing activated ester analogues (i.e., 
phenyl and 2,2,2-trifluoroethyl) were particularly problematic since 
the sterically larger activated esters slowed the initial Michael reac-
tion and the dianions were more prone to decomposition. Most 
importantly,  aromatization  of  the  C-/F-rings  of  the  octacyclic 
products was met with difficulty and led us to consider alternative 
approaches.
18  Benzyl sulfoxide
19  and benzyl sulfone
20  substituted 
ortho-toluates were also evaluated to achieve the desired naphthol 
annulation with (+)-9 or ent-9, but ultimately proved unsuccessful 
in the context of a two-directional double annulation (vide infra). 
We next envisaged a benzyl fluoride Michael–Claisen reaction 
sequence to generate naphthalenes after subsequent dehydrohalo-
genation.
21 Although there was no precedence for such a strategy, a 
benzyl fluoride annulation donor was attractive for several reasons: 
(1)  the  electronegative  fluorine  atom  should  stabilize  the  biaryl 
dianion,  (2)  the  small  atomic  radius  of  fluorine  should  provide 
minimal steric hinderance to the initial Michael reaction, (3) the 
strength of C–F bonds would disfavor α-elimination and SN2 dis-
placement of fluoride, and (4) despite the strength of C–F bonds, 
elimination  of  the  benzyl  fluoride  under  appropriate  conditions 
could lead to C- and F-ring aromatization.
22 The dianion of (±)-24 
was  brominated  with  (BrCF2)2  to  yield  the  bis-benzyl  bromide, 
which upon heating with TBAT
23 afforded bis-benzyl fluoride (±)-
25. After significant experimentation, the desired protected HMP-
Y1 derivatives (–)-27a and (+)-27b
24 were accessed from (+)-9 
and (±)-25 in a two-step procedure involving: (1) a bis-Michael–
Claisen reaction sequence promoted by LiTMP and MgBr2•OEt2 
to afford octacycles 26a and 26b and (2) the formal elimination of 
HF  by  heating  the  unpurified  reaction  product  in  2,2,2-
trifluoroethanol (TFE) to achieve aromatization of the C- and F-
rings and provide atropisomers (–)-27a and (+)-27b, which were 
readily separated and carried forward independently. Several fea-
tures of this sequence deserve comment. As we had hoped, the use 
of a bis-benzyl fluoride (±)-25 allowed for the initial bis-Michael 
addition to occur at –78 °C, thus minimizing decomposition of the 
dianion intermediate and of (+)-9. Addition of MgBr2•OEt2 mid 
annulation sequence was critical to promote the final intramolecu-
lar Claisen reactions and obviated the need to use an activated ester 
analogue. This discovery should help expand the substrate scope of 
the Michael–Claisen reaction sequence. Finally, the unique ability 
of TFE to promote the desired elimination is presumably due to its 
ability to strongly hydrogen bond with fluorine, and thus activate it 
for mild solvolysis. Indeed, use of ethanol in place of TFE only led 
to trace elimination. The employment of a benzyl fluoride annula-
tion-elimination  sequence  to  generate  naphthalene  derivatives  is 
without precedence and may prove to be a general method for the 
synthesis of naphthols. 
Global deprotection of (–)-27a and (+)-27b with aqueous HF 
followed  by  hydrogenolysis  afforded  HMP-Y1  (3a)  and  atrop-
HMP-Y1 (3b), respectively.
25 Heating 3a or 3b to 90 °C led to no 
detectable isomerization about the C2–C2' bond.
8 With no authen-
tic CD-spectra for natural 3a available, synthetic 3a and 3b were 
designated based on comparison to the CD spectrum of the glyco-
sylated derivative of 3a, HMP-Y6.
8  The axial stereochemistry of 
HMP-Y1 (3a) has not been rigorously determined, although model 
studies and the CD-spectra of HMP-Y6 and hibarimicinone (2a) 
suggest 3a possesses the aR configuration by the CD exciton chiral-
ity method.
2,26 Additionally, 3a, 2a, and hibarimicin A–G are all 
isolated  as  single  atropisomers.
26  We show that the axial stereo-
chemistry of 3a and 2a are not the result of thermodynamic equili-
bration (vide infra), and thus their biosynthetic relationship also 
argues that they possess the same relative configuration about the 
C2–C2' bond. Therefore, since the axial chirality of 2a was unam-
biguously determined,
4 3a can be assigned the aR configuration. 
Biomimetic Mono-Oxidation of Protected HMP-Y1. With a 
route to HMP-Y1 (3a) and atrop-HMP-Y1 (3b) established, we 
next attempted the biomimetic mono-oxidation of protected HMP-
Y1 derivatives. We discovered that the desired oxidation of ent-27a 
to the C-ring quinone (–)-29 could be achieved in low yield with 
CAN (Scheme 6), demonstrating the plausibility of our proposed 
biomimetic desymmetrizing oxidation. We speculate that the con-
gested biaryl may sterically occlude the approach of oxidants to the 
otherwise easily oxidized D-/E-ring system,
27 allowing oxidation of 
the more electron-deficient C-/F-rings. Despite this initial success, 
our attempts to optimize the CAN oxidation were met with difficul-
ty due to bis-oxidation and formation of nitrated byproducts. A 
survey of other oxidants also proved fruitless. 
Nevertheless, with naphthazarin (–)-29 in hand we next investi-
gated the desired biomimetic etherification reaction. Unfortunate-
ly, exposure of (–)-29 to the optimized conditions developed on 
our model system led to no observable etherification but rather 
only rapid MOM group cleavage. A screen of various acids and 
conditions also proved unsuccessful. The resistance of (–)-29 to 
undergo the desired etherification in contrast to the C-ring quinone 
derivative of (–)-18 was surprising. Since the major difference be-
tween the two systems is the lability of the MOM groups of (–)-29 
relative to the methyl group of (–)-18, we postulated that a free 
phenol at C1' might disfavor either acetonide decomposition or 
formation  of  the  necessary  ortho-quinone  methide  intermediate. 
This prompted us to replace the MOM group with a more acid-
stable protecting group. 
Scheme 6. Biomimetic Mono-Oxidation of Protected HMP-Y1. 
 
Additionally, our current biomimetic strategy would inevitably 
require a late-stage demethylation of the C4'–OMe methyl group. 
Ideally, one would remove the C4'–OMe methyl group as late in an 
eventual synthesis of hibarimicin B (1) as possible to protect the 
sensitive and stereochemically labile binaphthyl core (vide infra). 
However, the acidic conditions necessary to effect demethylation 
would be incompatible with the sensitive 2-deoxy- and 2,3-  
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aConditions: (a) LiHMDS, THF, –78 → 0 °C; then KHMDS, 0 °C → RT, 50–59%; (b) DMTSF, DTBMP, MeCN, 0 °C → RT; for (–)-35a, 75%; 
for (+)-35b, 89%; (c) for (–)-35a: DDQ, PhMe, 0 °C; for (+)-35b: DDQ, PhMe, 0 °C → RT; (d) HCl, ClCH2CH2Cl, 5 °C; for (–)-37a, 77% (two 
steps); for (+)-37b, 86% (two steps); (e) aq. HF, MeCN/THF; (f) H2, Pd(OH)2/C, EtOAc; then HCl, MeOH, air; for 2a, 81% (two steps); for 2b, 
60% (two steps); (g) aq. pH 7.5 NaH2PO4/NaOH buffer, MeOH, RT; from 2a, 84%; from 2b, 84%. 
Scheme 7. Synthesis of Unsymmetrical Biaryl (±)-34 via a Se-
lective Mono-Deprotonation of (±)-24 
 
aConditions:  (a)  LiTMP,  THF,  –78  °C;  then  (BrCF2)2,  82%;  (b) 
iPr2NEt, DMSO, 70 °C, 87%; (c) TFA, CH2Cl2, 0 °C → RT; (d) BCl3, 
CH2Cl2, –78 → 0 °C; (e) BnBr, K2CO3, DMF, 0 → 60 °C, 94% (three 
steps); (f) Me2C(OH)CN, Et3N, CHCl3, 97%; (g) LiTMP, THF, –78 
°C; then Ph(O)2SSPh, 71%. 
dideoxyglycosides of 1. The aforementioned reasons prompted us 
to investigate our alternative strategy for the synthesis of hibarimi-
cione  (2a)  and  HMP-P1  (6)  utilizing  an  unsymmetrical  two-
directional annulation reaction with biaryl (±)-34 (Scheme 7). 
Synthesis  of  the  Unsymmetrical  Biaryl  Annulation  Donor 
(±)-34. The unsymmetrical fully substituted biaryl (±)-34 presents 
unique synthesis challenges that are shared with the hibarimicins; 
cross-coupling technology to form such sterically hindered biaryls 
from electron-rich aromatics is limited.
3d In contrast, dimerization 
reactions to form hindered biaryls are robust and reliable (e.g., 22 
→ (±)-23). Thus we imagined that a practical synthesis approach 
to  (±)-34  would necessitate  the  desymmetrization  of  (±)-24.  A 
strategy to mono-functionalize (±)-24 involving radical bromina-
tion would inevitably result in an inefficient statistical mixture of 
benzylic bromides. However, we hypothesized that selective mono-
deprotonation of (±)-24 would be feasible since the initial carbani-
on would elevate the pKa of the remaining ortho-toluate due to a 
field effect. Indeed, we found that selective mono-deprotonation of 
(±)-24  at  C6'  could  be  achieved  with  1.25  equiv  of  LiTMP 
(Scheme 7). The resultant anion (±)-30 was then brominated with 
(BrCF2)2 to give benzyl bromide (±)-31 in 82% yield (Scheme 7). 
This single element of asymmetry was sufficient to introduce the 
remaining differential functionality of (±)-34. (±)-31 was oxidized 
to  aldehyde  (±)-32,
28  which  was  then  converted  to  tri-benzyl-
protected  biaryl  (±)-33  by  (1)  acid-promoted  removal  of  the 
MOM groups, (2) chemoselective cleavage of the C4'–OMe me-
thyl  group  with  BCl3,  and  (3)  global  reprotection  with  BnBr. 
Treatment of (±)-33 with a controlled source of hydrogen cyanide 
afforded a cyanophthalide intermediate.
29 Finally, double deproto-
nation of this intermediate with LiTMP followed by a short expo-
sure to S-phenyl benzenethiosulfonate chemoselectively installed 
the phenyl sulfide moiety
21 at C6 to provide biaryl (±)-34. The 
observed chemoselectivity in this reaction is a result of the much 
higher reactivity of the ortho-toluate anion relative to the cyanoph-
thalide anion. 
Completion  of  Hibarimicinone  (2a)  and  atrop-
Hibarimicinone (2b) via an Unsymmetrical Two-Directional 
Double Annulation. We anticipated that reaction of the lithiated 
cyanophthalide of (±)-34 with (+)-9 would directly construct the 
C-ring hydroquinone via a Kraus annulation, and reaction of the 
lithiated benzyl phenyl sulfide of (±)-34 with a second equivalent 
of (+)-9 would lead to the F-ring via a Michael–Claisen reaction 
sequence. We found that the desired transformations could be  
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Figure 2. (A) Upon standing in acidic methanol (1 M HCl) at RT, hibarimicinone (2a) and atrop-hibarimicinone (2b) undergo minor inter-
conversion and minimal conversion to HMP-P1 (6) (orange HPLC traces). (B) Exposure of 2a to pH 7.5 aqueous phosphate buffer at RT 
(blue HPLC traces) or (C) acidic methanol (1 M HCl) at 60 °C (red HPLC traces) resulted in isomerization to 2b and eventual formation of 
6. See SI for HPLC timecourses for 2b. 
achieved by treating a mixture of (±)-34 and (+)-9 with LiHMDS 
followed by subsequent addition of KHMDS mid annulation se-
quence under rigorously oxygen-free conditions to yield octacycle 
(–)-35a and (+)-35b as a ~1.3:1 mixture of atropisomers (Scheme 
8). The addition of KHMDS was crucial to facilitate the final in-
tramolecular  Claisen  reaction  to  construct  the  F-ring.
30  At  this 
stage, atropisomers (–)-35a and (+)-35b were separated and car-
ried forward independently. Elimination of the C6-benzylic phenyl 
sulfide  was  accomplished  with  dimethyl(methylthio)sulfonium 
tetrafluoroborate (DMTSF) to yield binaphthalenes (–)-36a and 
(+)-36b. It is worth reiterating at this point that the corresponding 
C6-benzyl sulfoxide and sulfone derivatives of (±)-34 ultimately 
proved unsuccessful in a two-directional annulation,
31 highlighting 
the  difficulty  to  achieve  naphthol  annulations  in  the  context  of 
complex molecule synthesis. To the best of our knowledge, this is 
the first example of a benzyl sulfide Michael–Claisen reaction se-
quence  to  generate  naphthalenes,  and  together  with  the  benzyl 
fluoride Michael–Claisen reaction sequence reported offer two new 
alternatives to approach challenging naphthol annulations. 
Oxidation of (–)-36a and (+)-36b with DDQ produced the cor-
responding C-ring quinones. Exposure of the respective quinones 
to anhydrous HCl promoted the desired biomimetic etherification 
to yield nonacycles (–)-37a and (+)-37b. This successful etherifi-
cation of the benzyl protected naphthazarins, in contrast to MOM-
protected (–)-29, confirmed our suspicion that the nature of the 
C1'-phenol has far-reaching stereoelectronic effects on this system. 
With  the  complete  skeletons  of  2a  and  2b  in  hand,  all  that  re-
mained  to  complete  the  syntheses  was  global  deprotection  and 
oxidation of the D-ring. Deprotection of the acid-labile protecting 
groups was accomplished upon exposure to HF. Finally, the benzyl 
groups  were  removed  via  hydrogenolysis,  and  after  addition  of 
acidic methanol, filtering, and exposure to air, hibarimicinone (2a) 
and  atrop-hibarimicinone (2b)  were  formed.  All  of  the  spectro-
scopic data for 2a and 2b match those reported
4,8,26 and thereby 
confirmed the structure of 2b. 
Discovery of a pH-Dependent Rotational Barrier About the 
C2–C2'  Bond  in  Hibarimicinone  (2a)  and  atrop-
Hibarimicinone (2b). The addition of acidic methanol prior to 
aerobic oxidation was crucial to prevent isomerization between 2a 
and 2b and formation of HMP-P1 (6).
25,32 Upon prolonged han-
dling or standing at ambient temperatures in acidic methanol (1 M 
HCl), we observed minor interconversion between 2a and 2b min-
imal formation of 6 (Figure 2A). However, simple exposure of 2a 
and 2b,  independently,  to  pH  7.5  buffered  methanol  led  to the 
formation of 6 in 84% yield in both cases (Scheme 8). Monitoring 
these  transformations  by  HPLC  revealed  that  nearly  complete 
isomerization about the C2–C2' bond (2a ↔ 2b) had occurred 
within 4 hours
 while formation of 6 was almost complete after 24 
hours (Figure 2B).
8 Together, these observations suggest that the 
rotational barriers about C2–C2' for 2a and 2b are pH-dependent. 
 
Figure 3. A proposed model to explain the pH-dependent rotational 
barrier about the C2–C2' bond of 2a and 2b. Only the CDEF-ring 
system is depicted for brevity. 
These findings are particularly interesting owing to prior obser-
vations that heating 2a in neutral methanol at 60 °C leads to nearly 
complete interconversion to 2b in 30 minutes and ultimately com-
plete  cyclization  to  yield  6  after  90  minutes.
1i,2,26  However,  we 
found that heating either 2a or 2b to 60 °C in acidic methanol (1 M 
HCl) led to only partial interconversion between 2a and 2b and 
minor conversion to 6 after 90 minutes (Figure 2C). This suggests 
that the observed rapid rotation at 60 °C in neutral methanol has 
less to do with providing the necessary thermal energy to surpass 
the  intrinsic  activation  barrier  about  C2–C2'  in  the  uncharged 
forms of 2a/2b (38a/38b in Figure 3), but rather enables access to 
the deprotonated form of 2a and 2b (39a/39b in Figure 3) via 
inter-  or  intramolecular  proton  transfer.  Rapid  interconversion 
between 37a and 37b can then follow through a transition state 
that  is  stabilized  by  π-electron  overlap,
1b,33  as  depicted  in  cross-
conjugated resonance structures 40a and 40b. Consequently, vari-
ables that affect the equilibrium between 38a and 39a, and 38b and 
39b will affect the rate of isomerization. The addition of acid to the 
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media inhibits access to species 39a and 39b by driving the equilib-
rium  toward  38a  and  38b,  and  thus  disfavors  isomerization.  In 
contrast, heat (60 °C) should promote equilibration between the 
protonation states and thus facilitate isomerization. Our discovery 
of the pH-dependent barrier demonstrates the delicate nature of 
the C2–C2' which must be accommodated in an eventual synthesis 
of hibarimicin B (1).
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Conclusion 
Enantioselective  syntheses  of  hibarimicinone  (2a)  and  atrop-
hibarimicionone  (2b),  and  the  first  total  syntheses  of  HMP-Y1 
(3a), atrop-HMP-Y1 (3b), and HMP-P1 (6) have been accom-
plished. The complete carbon skeleton of each natural product was 
assembled  via  a  convergent  two-directional  annulation  strategy. 
The use of a racemic biaryl in conjunction with the two-directional 
annulation strategy enabled both atropisomers of the natural prod-
ucts  to  be  separately  constructed  and  fully  characterized,  thus 
providing the first reported full characterization of 2b, 3a, 3b, and 
6. Additionally during the pursuit of this annulation strategy, we 
encountered numerous challenges when conducting naphthol an-
nulation reactions. Consequently, we developed two valuable Mi-
chael–Claisen reaction sequences to construct complex naphthols 
that might find use as general methods. The mild conditions need-
ed  to  dehydrohalogenate  the  benzyl  fluoride  intermediates  are 
particularly noteworthy given the strength of C–F bonds. 
The plausibility of our proposed biosynthesis was also validated 
by the demonstration that a desymmetrizing mono-oxidation of the 
C-ring can be conducted on protected HMP-Y1 derivatives. Over-
oxidation to the bis-C-/F-ring quinone was also observed, but natu-
ral products corresponding to such a double oxidation have not 
been isolated in nature or during mutagenesis studies. This perhaps 
suggests that an enzyme mediates this key biosynthetic transfor-
mation, but how 3a is only mono-oxidized remains unclear. 
After  the  key  two-directional  annulations,  only  three  and  five 
steps were needed to complete HMP-Y1 (3a) and hibarimicinone 
(2a), respectively. In the case of 2a, these steps include a biomimet-
ic  etherification  to  install  the  B-ring  cyclic  ether  via  an  ortho-
quinone  methide  intermediate.  The  success  of  this  reaction  re-
quired an acid-stable protecting group on the C1'-phenol owing to 
subtle  yet  far-reaching  stereoelectronic  effects  imparted  by  the 
naphthazarin-naphthalene system. The peculiarities and sensitivity 
of  this  system  are  also  highlighted  by  our  discovery  of  the  pH-
dependent rotational barrier about the C2–C2' bond. These par-
ticular observations provide crucial information that will facilitate 
an eventual synthesis of hibarimicin B (1). 
Lastly, the intermediate (–)-37a will be highly useful in an even-
tual total synthesis of 1; it is suitably protected with orthogonal 
protecting groups to allow for the sequential installation of the 2-
deoxy- and 2,3-dideoxyglycosides prior to deprotection of the sen-
sitive binaphthyl core of the molecule. Future studies toward the 
total synthesis of 1 will be reported in due course. 
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